GLENMARK PHARMACEUTICALS LTD. - 532296 - Disclosure Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark is the first company to launch in India a Triple FDC of Teneligliptin + Pioglitazone + Metformin for Adults with Type 2 Diabetes & High Insulin Resistance GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA approval for Nicardipine Hydrochloride Capsules, 20 mg and 30 mg GLENMARK PHARMACEUTICALS LTD. - 532296 - Glenmark Pharmaceuticals Ltd. To Divest Its Cardiac Brand, Razel(r), In India And Nepal To J.B. Chemicals & Pharmaceuticals Limited
Glenmark Pharmaceuticals Ltd. to divest its Cardiac brand, Razel(r), in India and Nepal to J.B. Chemicals & Pharmaceuticals Limited
USFDA issues warning letter to Glenmark Pharma for lapses at Goa plant
The US health regulator has pulled up drug maker Glenmark Pharmaceuticals for manufacturing lapses, including failure to establish required laboratory control mechanisms, at its Goa-based manufacturing plant. In a warning letter addressed to Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha, the US Food and Drug Administration (USFDA) pointed out various lapses at the company's Bardez-based facility in Goa, which produces drug formulations. The US Health regulator noted that the "warning letter summarises significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals". It further said: "Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated..." The USFDA inspected the manufacturing facility from May 12, 2022, to May 20, 2022. In the warning letter, the US health regulator pointed out the company's failure "to...
Glenmark Pharma needs many things to fall in place to stand tall
Investors will keep a close eye on the execution of the company's plans. Nuvama Research report dated 18 November sums it up well. GLENMARK PHARMACEUTICALS LTD. - 532296 - Disclosure Of Related Party Transactions For The Half Year Ended 30Th September, 2022
Disclosure of Related Party Transactions for the half year ended 30th September, 2022
Neutral Glenmark Pharma; target of Rs 420: Motilal Oswal
Motilal Oswal recommended Neutral rating on Glenmark Pharma with a target price of Rs 420 in its research report dated November 14, 2022.
USFDA issues warning letter to Glenmark Pharma's Goa unit
The US drug regulator had inspected the Glenmark's Goa facility in May 2022 and issued Official Action Indicated (OAI) GLENMARK PHARMACEUTICALS LTD. - 532296 - Update On The US FDA Inspection Of Glenmark'S Goa Manufacturing Facility
Update on the US FDA inspection of Glenmark's Goa manufacturing facility